The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant attention within the United Kingdom , prompting a notable shift in hormone trends. Access these treatments remains a complex landscape, with National Health Service coverage currently limited and specialist practices offering therapy at a premium